Get the Stockscreener App
8.05
4.14%
0.32
After Hours:
8.01
-0.04
-0.50%
CorMedix Inc stock is traded at $8.05, with a volume of 1.16M.
It is up +4.14% in the last 24 hours and up +13.70% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$7.73
Open:
$7.85
24h Volume:
1.16M
Relative Volume:
0.84
Market Cap:
$631.46M
Revenue:
$311.71M
Net Income/Loss:
$163.05M
P/E Ratio:
4.0585
EPS:
1.9835
Net Cash Flow:
$172.79M
1W Performance:
+7.62%
1M Performance:
+13.70%
6M Performance:
-25.32%
1Y Performance:
-27.87%
1-Day Range:
$7.81
$8.1143
1-Week Range:
$7.51
$8.1143
52-Week Range:
$6.125
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
8.05 | 606.36M | 311.71M | 163.05M | 172.79M | 1.9835 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
What CorMedix says before the bell May 14: earnings and update - Stock Titan
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 - Yahoo Finance
CorMedix stock falls 5% on fourth quarter earnings miss - Investing.com
Cormedix Stock Pre-Market (+6.2%) : Technical Move Ahead of Key Q2 Catalyst - Trefis
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com
CorMedix banks on DefenCath sales in Q4 as Melinta adds upside - MSN
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
HC Wainwright & Co. Maintains CorMedix (CRMD) Buy Recommendation - MSN
[ARS] CorMedix Inc. SEC Filing - Stock Titan
CorMedix (CRMD) posts 2025 profit, seeks approval of key charter and governance changes - Stock Titan
CorMedix | 4: Statement of changes in beneficial ownership of securities-Officer Hurlburt Elizabeth - Moomoo
H.C. Wainwright reiterates CorMedix stock rating on trial results By Investing.com - Investing.com India
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating - Moomoo
CorMedix stock rating maintained at outperform by Citizens By Investing.com - Investing.com India
A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $13 to $15 - Moomoo
H.C. Wainwright reiterates CorMedix stock rating on trial results - Investing.com UK
H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk - marketscreener.com
CorMedix stock rating maintained at outperform by Citizens - Investing.com Australia
symbol__ Stock Quote Price and Forecast - CNN
Positive REZZAYO Phase III Prophylaxis Data Might Change The Case For Investing In CorMedix (CRMD) - Sahm
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance - MSN
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $15 - Moomoo
CorMedix reports positive Phase III results for rezafungin trial - Investing.com UK
RBC Capital raises CorMedix stock price target on phase III data - Investing.com UK
RBC Capital raises CorMedix stock price target on phase III data By Investing.com - Investing.com South Africa
CorMedix files to sell 6.32M shares of common stock for holders - MSN
CorMedix nears an 11-month low after earnings miss - MSN
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study - Benzinga
CorMedix Announces Positive Phase III Results for Rezafungin in Preventing Invasive Fungal Diseases in Stem Cell Transplant Patients - Minichart
Cormedix Therapeutics announces positive topline results from phase III Respect trial - marketscreener.com
Cormedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial - TradingView
CorMedix reports positive Phase III results for rezafungin trial By Investing.com - Investing.com South Africa
Phase III ReSPECT success boosts CorMedix (CRMD) REZZAYO prophylaxis plans - Stock Titan
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients - ChartMill
CorMedix shares slip after unveiling lower revenue outlook for 2026 - MSN
(CRMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Do options traders know something about CorMedix stock we don't? - MSN
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):